Oruka Therapeutics, Inc. financial data

Symbol
ORKA on Nasdaq
Location
Menlo Park, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2299% % -9.3%
Debt-to-equity 3.9% % -24%
Return On Equity -25% % 48%
Return On Assets -24% % 36%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49,542,691 shares 32%
Common Stock, Shares, Outstanding 48,722,309 shares 30%
Entity Public Float $371,500,000 USD 836%
Common Stock, Value, Issued $49,000 USD 32%
Weighted Average Number of Shares Outstanding, Basic 42,095,951 shares 1216%
Weighted Average Number of Shares Outstanding, Diluted 42,095,951 shares 1216%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $100,640,000 USD 34%
General and Administrative Expense $21,411,000 USD 64%
Operating Income (Loss) $122,051,000 USD -39%
Nonoperating Income (Expense) $16,618,000 USD 278%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $105,433,000 USD -26%
Earnings Per Share, Basic 2.37 USD/shares 93%
Earnings Per Share, Diluted 2.37 USD/shares 93%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $46,935,000 USD -24%
Marketable Securities, Current $290,109,000 USD -7.6%
Other Assets, Current $537,000 USD -10%
Assets, Current $343,857,000 USD -8.8%
Property, Plant and Equipment, Net $288,000 USD 78%
Operating Lease, Right-of-Use Asset $1,830,000 USD 109%
Other Assets, Noncurrent $103,000 USD 140%
Assets $488,617,000 USD 23%
Accounts Payable, Current $571,000 USD 137%
Employee-related Liabilities, Current $109,000 USD -43%
Liabilities, Current $15,374,000 USD 18%
Operating Lease, Liability, Noncurrent $1,313,000 USD 74%
Liabilities $16,687,000 USD 21%
Accumulated Other Comprehensive Income (Loss), Net of Tax $546,000 USD
Retained Earnings (Accumulated Deficit) $189,157,000 USD -126%
Stockholders' Equity Attributable to Parent $471,930,000 USD 23%
Liabilities and Equity $488,617,000 USD 23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $20,869,000 USD -1266%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 545,000,000 shares 0%
Common Stock, Shares, Issued 48,722,309 shares 30%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,528,000 USD 4.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $46,935,000 USD -24%
Deferred Tax Assets, Valuation Allowance $48,716,000 USD 129%
Deferred Tax Assets, Gross $49,140,000 USD 129%
Operating Lease, Liability $1,932,000 USD 100%
Depreciation $16,000 USD
Payments to Acquire Property, Plant, and Equipment $13,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $104,846,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid $2,291,000 USD 84%
Property, Plant and Equipment, Gross $222,000 USD -3.1%
Operating Lease, Liability, Current $619,000 USD 191%
Lessee, Operating Lease, Liability, to be Paid, Year Two $768,000 USD 55%
Lessee, Operating Lease, Liability, to be Paid, Year One $822,000 USD 123%
Operating Lease, Weighted Average Discount Rate, Percent 0.1307 pure -27%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $359,000 USD 31%
Lessee, Operating Lease, Liability, to be Paid, Year Three $397,000 USD 4.5%
Deferred Tax Assets, Operating Loss Carryforwards $6,398,000 USD 183%
Unrecognized Tax Benefits $1,819,000 USD 74%
Lessee, Operating Lease, Liability, to be Paid, Year Four $304,000 USD
Operating Lease, Payments $63,000 USD 174%
Additional Paid in Capital $657,561,000 USD 42%
Share-based Payment Arrangement, Expense $24,240,000 USD 62%